Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

Core Viewpoint - Vericel Corporation reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.09, marking an earnings surprise of -155.56% [1] Financial Performance - The company posted revenues of $52.6 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.73$51.28 million a year ago [2] - Over the last four quarters, Vericel has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Vericel shares have declined approximately 26.3% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current Zacks Rank for Vericel is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of$65.24 million, and for the current fiscal year, it is $0.32 on revenues of$286.96 million [7] - The estimate revisions trend for Vericel is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Biomedical and Genetics industry, to which Vericel belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]